Advanced seminoma at stage IIB or III is typically approached with cisplatin-based chemotherapy. When a patient is medically unsuitable for cisplatin, the clinical pathway diverges and requires a structured, evidence-based alternative approach.
This protocol applies to patients with seminoma stage IIB–III who have a documented unsuitability for cisplatin-based chemotherapy. That contraindication is the defining condition that determines which treatment pathway is indicated here.
For patients unfit for the standard cisplatin-based approach, a carboplatin-based chemotherapy regimen is the indicated alternative. The full combination, eligibility criteria, and clinical decision algorithm are available in the structured protocol below — only a partial overview is shown here.
DOI: 10.1016/j.annonc.2022.01.002
Only patients unfit for cisplatin-based ChT should be treated with carboplatin-based ChT (carboplatin, etoposide and bleomycin), which is inferior to BEP.
View source ↗